CTNND2 moderates the pace of synaptic maturation and links human evolution to synaptic neoteny.
CP: Developmental biology
CP: Neuroscience
CTNND2
SRGAP2
SRGAP2C
SYNGAP1
autism spectrum disorder
dendritic spine
gene duplication
human brain evolution
human-specific gene
intellectual disability
intrinsic excitability
neoteny
postsynaptic scaffold
synapse
synaptic transmission
synaptogenesis
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
16
05
2023
revised:
01
05
2024
accepted:
10
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
Human-specific genes are potential drivers of brain evolution. Among them, SRGAP2C has contributed to the emergence of features characterizing human cortical synapses, including their extended period of maturation. SRGAP2C inhibits its ancestral copy, the postsynaptic protein SRGAP2A, but the synaptic molecular pathways differentially regulated in humans by SRGAP2 proteins remain largely unknown. Here, we identify CTNND2, a protein implicated in severe intellectual disability (ID) in Cri-du-Chat syndrome, as a major partner of SRGAP2. We demonstrate that CTNND2 slows synaptic maturation and promotes neuronal integrity. During postnatal development, CTNND2 moderates neuronal excitation and excitability. In adults, it supports synapse maintenance. While CTNND2 deficiency is deleterious and results in synaptic loss of SYNGAP1, another major ID-associated protein, the human-specific protein SRGAP2C, enhances CTNND2 synaptic accumulation in human neurons. Our findings suggest that CTNND2 regulation by SRGAP2C contributes to synaptic neoteny in humans and link human-specific and ID genes at the synapse.
Identifiants
pubmed: 39352808
pii: S2211-1247(24)01148-3
doi: 10.1016/j.celrep.2024.114797
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
114797Informations de copyright
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.